Finanzen von Cara Therapeutics Inc (CARA)CARACara Therapeutics Inc

Cara Therapeutics Inc (CARA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Collaborative revenue, accounting for 50.8% of total sales, equivalent to $1.30M. Another important revenue stream is Other revenue . Understanding this composition is critical for investors evaluating how CARA navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Cara Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -206.61%, while the net margin is -488.11%. These profitability ratios, combined with a Return on Equity (ROE) of -221.25%, provide a clear picture of how effectively CARA converts its operational activities into shareholder value.

In the context of the broader market, CARA competes directly with industry leaders such as PASG and LGVN. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CARA's gross margin of 100.00% stands against PASG's N/A and LGVN's 63.41%. Such benchmarking helps identify whether Cara Therapeutics Inc is trading at a premium or discount relative to its financial performance.